{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:35:52Z","timestamp":1786649752650,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To evaluate the role of nimotuzumab in combination with chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) through progress-free survival, changes in tumor marker expression and adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 59 NSCLC patients were randomized into two groups. The treatment group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 30) received nimotuzumab (200 mg) with docetaxel (60 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and carboplatin (area under curve = 5), whereas the control group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 29) received chemotherapy at the same dosage. All patients received two cycles of treatment lasting for 42 days. The serum tumor biomarker levels were measured on the day before treatment and at 60 days after treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The efficacy of treatment for the treatment and control groups were 36.7% and 27.6%, respectively; this difference was not statistically significant. However, progression-free survival (PFS) was significantly prolonged by 1 month in the treatment group. Peripheral blood CYFRA21-1 decreased significantly during treatment with a more extensive decrease in the treatment group, although the difference between the groups was not statistically significant. The neuron-specific enolase levels significantly decreased across all 59 patients. The carcinoembryonic antigen levels decreased significantly in the treatment group, but remained stable in the control group throughout the treatment period. Nimotuzumab was well tolerated by patients with only three cases of Grades I and II skin rash and no other toxic symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Nimotuzumab with docetaxel and carboplatin can enhance the short-term clinical efficacy by extending the duration of PFS and was generally well tolerated by patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.163836","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T23:55:26Z","timestamp":1441065326000},"page":"S32-S37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A clinical trial on docetaxel and carboplatin therapy with or without nimotuzumab for the treatment of advanced nonsmall cell lung cancer"],"prefix":"10.4103","volume":"11","author":[{"given":"Daliang","family":"Qi","sequence":"first","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cui","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbiao","family":"Huang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhuo","family":"Yang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xin","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Angelique","family":"Qi","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,8,31]]},"reference":[{"key":"R2-20260109","first-page":"1151","article-title":"Membrane-anchored forms of EGF stimulate focus formation and intercellular communication","volume":"6","author":"Dobashi","year":"1991","journal-title":"Oncogene"},{"key":"R3-20260109","first-page":"327","article-title":"Targeting epidermal growth factor receptor signaling: Early results and future trends in oncology","volume":"35","author":"Lage","year":"2003","journal-title":"Ann Med"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1634\/theoncologist.11-3-274","article-title":"Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC","volume":"11","author":"Maione","year":"2006","journal-title":"Oncologist"},{"key":"R8-20260109","first-page":"1313","article-title":"Clinical investigation of weekly cisplatin and vinorelbine with concurrent radiation therapy for locally advanced non-small cell lung cancer","volume":"38","author":"Furihata","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"R9-20260109","first-page":"1256","article-title":"Strategy for marginally resectable lung cancer","volume":"38","author":"Kaji","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bjc.6604222","article-title":"Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status","volume":"98","author":"Akashi","year":"2008","journal-title":"Br J Cancer"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ijc.10647","article-title":"Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody","volume":"101","author":"Crombet-Ramos","year":"2002","journal-title":"Int J Cancer"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00280-010-1379-9","article-title":"Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","volume":"67","author":"Bebb","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1055\/s-0030-1255636","article-title":"Lung cancer - Historical development, current status, future prospects","volume":"64","author":"Goeckenjan","year":"2010","journal-title":"Pneumologie"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4161\/cbt.9.5.10981","article-title":"Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck","volume":"9","author":"Rodr\u00edguez","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","author":"Ramakrishnan","year":"2009","journal-title":"MAbs"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","article-title":"Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients","volume":"22","author":"Crombet","year":"2004","journal-title":"J Clin Oncol"},{"key":"R17-20260109","first-page":"881","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"87","author":"Duffaud","year":"2000","journal-title":"Bull Cancer"},{"issue":"15 Pt 2","key":"R18-20260109","doi-asserted-by":"crossref","first-page":"s4597","DOI":"10.1158\/1078-0432.CCR-07-0335","article-title":"Antibodies to the epidermal growth factor receptor in non small cell lung cancer: Current status of matuzumab and panitumumab","volume":"13","author":"Socinski","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0186","article-title":"Adjuvant therapy in non-small cell lung cancer: Current and future directions","volume":"15","author":"Sangha","year":"2010","journal-title":"Oncologist"},{"issue":"8 Pt 2","key":"R20-20260109","first-page":"3S119","article-title":"Stage IV NSCLC. Biological treatments of lung cancer in 2008. and in the near future","volume":"25","author":"Bergot","year":"2008","journal-title":"Rev Mal Respir"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2008-0153","article-title":"Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer","volume":"14","author":"Gridelli","year":"2009","journal-title":"Oncologist"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2174\/092986711795471383","article-title":"Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: Clinical and molecular considerations","volume":"18","author":"Pallis","year":"2011","journal-title":"Curr Med Chem"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1535-7163.465.3.4","article-title":"Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor\/extracellular signal-regulated kinase 1\/2 and EGF receptor\/Akt pathway for proliferation","volume":"3","author":"Ono","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"Suppl. 20","key":"R24-20260109","article-title":"Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","volume":"26","author":"Bebb","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","article-title":"Non-small-cell lung cancer","volume":"378","author":"Goldstraw","year":"2011","journal-title":"Lancet"},{"key":"R26-20260109","first-page":"1765","article-title":"The NQO1FNx012\/FNx012 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer","volume":"25","author":"Kolesar","year":"2011","journal-title":"Oncol Rep"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1097\/JTO.0b013e3181ea510a","article-title":"Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients","volume":"5","author":"Al-Saad","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000074432","article-title":"Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors","volume":"24","author":"Molina","year":"2003","journal-title":"Tumour Biol"},{"key":"R29-20260109","first-page":"3613","article-title":"Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer","volume":"19","author":"Foa","year":"1999","journal-title":"Anticancer Res"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejcts.2007.05.014","article-title":"Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer","volume":"32","author":"Matsuoka","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2007.07.002","article-title":"Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer","volume":"58","author":"Mizuguchi","year":"2007","journal-title":"Lung Cancer"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.lungcan.2007.10.026","article-title":"Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC","volume":"60","author":"Muley","year":"2008","journal-title":"Lung Cancer"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000152945","article-title":"Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: External validation of a prognostic score","volume":"29","author":"Blankenburg","year":"2008","journal-title":"Tumour Biol"},{"key":"R34-20260109","first-page":"1953","article-title":"CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients","volume":"24","author":"Muley","year":"2004","journal-title":"Anticancer Res"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","article-title":"Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine","volume":"39","author":"Zweig","year":"1993","journal-title":"Clin Chem"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5483\/BMBRep.2008.41.9.615","article-title":"Biomarkers for the lung cancer diagnosis and their advances in proteomics","volume":"41","author":"Sung","year":"2008","journal-title":"BMB Rep"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000227660","article-title":"CYFRA 21-1: An indicator of survival and therapeutic effect in lung cancer","volume":"54","author":"Takei","year":"1997","journal-title":"Oncology"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1200\/JCO.2007.13.0856","article-title":"Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer","volume":"25","author":"Butts","year":"2007","journal-title":"J Clin Oncol"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3816\/CLC.2010.n.026","article-title":"Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer","volume":"11","author":"Spigel","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1634\/theoncologist.10-9-760","article-title":"Nimotuzumab: Evidence of clinical benefit without rash","volume":"10","author":"Allan","year":"2005","journal-title":"Oncologist"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/1078-0432.CCR-09-3042","article-title":"Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study","volume":"16","author":"Rojo","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511001-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:00Z","timestamp":1786647480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511001-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":40,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.163836","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}